RedHill reports H1 2026 results after Rebyota, Clenpiq deal and Talicia exit

RedHill Biopharma reported operational highlights and financial results for the six months ended June 30, 2026, on September 30, 2026. Following the divestment of RedHill's 70% stake in Talicia, which brought $18 million in upfront cash and the possibility of up to $35 million more in sales-based milestones, the company used that money to pay Ferring $12 million upfront for exclusive global and U.S. commercialization rights to Rebyota and Clenpiq, plus future milestones and tiered royalties.¹ RedHill had sold its entire 70% interest in Talicia Holding Inc. to Apotex in August 2026.¹

On the pipeline, opaganib has been granted the FDA's rare pediatric disease designation for neuroblastoma, with potential to receive an accompanying Priority Review Voucher.¹ The company said new preclinical data on opaganib as an add-on therapy in neuroblastoma and triple-negative breast cancer models were presented at the 2026 AACR Annual Meeting, showing opaganib may enhance an oxaliplatin plus doxorubicin chemotherapy combination in high-risk neuroblastoma by destabilizing n-Myc, and that opaganib pre-treatment followed by low-dose diABZI potentiated STING-mediated effects in triple-negative breast cancer models.¹ The company also said opaganib Ebola development discussions are ongoing with regional health authorities in Africa. For Crohn's disease, new in vitro data from spot and phage assays showed RHB-204 achieved MAP killing comparable to RHB-104, at lower doses of key active ingredients, supporting a Phase 2-ready study design with a smaller sample size.¹

Financially, RedHill's cash balance as of June 30, 2026 was $5.3 million.¹ Net cash provided by financing activities was $5.4 million, primarily from the June 2026 private placement.¹ Net loss for the period was $6.1 million, compared with $4.1 million in the first half of 2025.¹